Strides Pharma Science Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 9,994.27 million compared to INR 8,970.97 million a year ago. Revenue was INR 10,352.75 million compared to INR 9,205.56 million a year ago. Net loss was INR 1,313.43 million compared to net income of INR 228.25 million a year ago. Basic loss per share from continuing operations was INR 14.54 compared to basic earnings per share from continuing operations of INR 0.47 a year ago. Diluted loss per share from continuing operations was INR 14.54 compared to diluted earnings per share from continuing operations of INR 0.47 a year ago. Basic loss per share was INR 14.54 compared to basic earnings per share of INR 2.54 a year ago. Diluted loss per share was INR 14.54 compared to diluted earnings per share of INR 2.54 a year ago.
For the six months, sales was INR 19,294.21 million compared to INR 18,371.71 million a year ago. Revenue was INR 19,739.14 million compared to INR 18,741.78 million a year ago. Net loss was INR 1,384.56 million compared to INR 1,130.67 million a year ago. Basic loss per share from continuing operations was INR 15.33. Diluted loss per share from continuing operations was INR 15.33. Basic loss per share was INR 15.33 compared to INR 12.58 a year ago. Diluted loss per share was INR 15.33 compared to INR 12.58 a year ago.